Patents by Inventor Stephen Berasi
Stephen Berasi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970524Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: GrantFiled: December 17, 2020Date of Patent: April 30, 2024Assignees: PFIZER INC., BOSTON MEDICAL CENTER CORPORATIONInventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Patent number: 11365253Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.Type: GrantFiled: June 8, 2018Date of Patent: June 21, 2022Assignees: Pfizer Inc., Boston Medical Center CorporationInventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
-
Publication number: 20210214414Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: ApplicationFiled: December 17, 2020Publication date: July 15, 2021Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Patent number: 11008373Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: December 6, 2018Date of Patent: May 18, 2021Assignee: Wyeth, LLC.Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Patent number: 10906955Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: GrantFiled: June 1, 2018Date of Patent: February 2, 2021Assignees: Pfizer Inc., Boston Medical Center CorporationInventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Publication number: 20200157212Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.Type: ApplicationFiled: June 8, 2018Publication date: May 21, 2020Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
-
Publication number: 20190241634Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: ApplicationFiled: December 6, 2018Publication date: August 8, 2019Inventors: Stephen BERASI, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Patent number: 10196433Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: May 5, 2017Date of Patent: February 5, 2019Assignee: Wyeth LLCInventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Publication number: 20180346542Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: ApplicationFiled: June 1, 2018Publication date: December 6, 2018Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Publication number: 20180134762Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: ApplicationFiled: May 5, 2017Publication date: May 17, 2018Inventors: Stephen BERASI, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Patent number: 9688735Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: January 5, 2015Date of Patent: June 27, 2017Assignee: Wyeth LLCInventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Publication number: 20160207973Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: ApplicationFiled: January 5, 2015Publication date: July 21, 2016Inventors: Stephen BERASI, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
-
Patent number: 8952131Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: GrantFiled: August 17, 2011Date of Patent: February 10, 2015Assignee: Wyeth LLCInventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Wozney, Howard Seeherman, Z. Sean Juo, Valerie P. Calabro, Christopher Todd Brown
-
Publication number: 20120046227Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Applicant: WYETH LLCInventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Wozney, Howard Seeherman, Z. Sean Juo, Valerie Calabro, Christopher Todd Brown
-
Patent number: 7763441Abstract: The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.Type: GrantFiled: March 13, 2007Date of Patent: July 27, 2010Assignee: WyethInventors: Stephen Berasi, Christine Huard, Dongmei Li, Heather Shih, Ying Sun, Janet Paulsen, Eugene L. Brown, Ruth Gimeno, Robert Martinez
-
Publication number: 20090220983Abstract: The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2.Type: ApplicationFiled: February 26, 2009Publication date: September 3, 2009Applicant: WyethInventors: Joanne Archambault, Stephen Berasi, Andrew Dorner, Scott Jelinsky
-
Publication number: 20070270331Abstract: The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.Type: ApplicationFiled: March 13, 2007Publication date: November 22, 2007Inventors: Stephen Berasi, Christine Huard, Dongmei Li, Heather Shih, Ying Sun, Janet Paulsen, Eugene Brown, Ruth Gimeno, Robert Martinez